Transition Therapeutics Inc. (Elan) announced the results of a clinical study of drug candidate ELND005 in young adults with Down syndrome. The study focuses on neuropsychiatric symptoms associated with Alzheimer’s disease and cognition in people with Ds.
In our September 2013 Newsflash, LuMind Foundation’s Chief Scientific Officer Dr. Harpold explained the ELND005 study. Essentially, ELND005 is a molecule that may hold the potential to improve cognition in Ds, in part, by reducing aggregation of beta-amyloid, which is a product of the amyloid precursor protein (APP) encoded by a gene on chromosome 21 — thus preventing the intraneuronal buildup of beta-amyloid plaques that most people with Ds develop by their 40s associated with Alzheimer’s disease.
LuMind-supported research has previously shown reducing the levels of APP and/or certain of the APP-derived beta-amyloid products overcome specific cognitive and neurodegenerative Alzheimer’s disease-related effects in mouse models of Down syndrome.
LuMind has also been working with Transition Therapeutics to supported clinical trial participant recruitment. Your donations and support helped advance this clinical trial!